Galecto
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Galecto and other ETFs, options, and stocks.About GLTO
Galecto, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The firm is also involved in the development of small molecule inhibitors of galectin-3 and LOXL2.
CEOHans Thalsgård Schambye
CEOHans Thalsgård Schambye
Employees5
Employees5
HeadquartersBoston, Massachusetts
HeadquartersBoston, Massachusetts
Founded2011
Founded2011
Employees5
Employees5
GLTO Key Statistics
Market cap30.49M
Market cap30.49M
Price-Earnings ratio-1.89
Price-Earnings ratio-1.89
Dividend yield—
Dividend yield—
Average volume159.58K
Average volume159.58K
High today$23.72
High today$23.72
Low today$21.00
Low today$21.00
Open price$21.35
Open price$21.35
Volume256.92K
Volume256.92K
52 Week high$33.60
52 Week high$33.60
52 Week low$2.01
52 Week low$2.01
Stock Snapshot
As of today, Galecto(GLTO) shares are valued at $22.79. The company's market cap stands at 30.49M, with a P/E ratio of -1.89.
On 2025-12-04, Galecto(GLTO) stock traded between a low of $21.00 and a high of $23.72. Shares are currently priced at $22.79, which is +8.5% above the low and -3.9% below the high.
The Galecto(GLTO)'s current trading volume is 256.92K, compared to an average daily volume of 159.58K.
In the last year, Galecto(GLTO) shares hit a 52-week high of $33.60 and a 52-week low of $2.01.
In the last year, Galecto(GLTO) shares hit a 52-week high of $33.60 and a 52-week low of $2.01.
People also own
Based on the portfolios of people who own GLTO. This list is generated using Robinhood data, and it’s not a recommendation.